{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 52,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "other",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a process flow to show the evolution of data from preliminary Phase 1 to updated data shared with the FDA.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/27",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.55,
        "x": 0.41,
        "y": 0.8
      },
      "kind": "callout",
      "text": "ARROS-1 update expected at a medical meeting in 2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93855539-684a-41ff-8a81-fabe6441bc1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.07,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "CNS, Central Nervous System; MTD, Maximum Tolerated Dose; QD, Once Daily.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efabdb77-5a8a-4851-8549-93cc2b0184bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.08,
        "y": 0.24
      },
      "kind": "list",
      "text": "Preliminary Phase 1 Dose Escalation Data: Data cut-off: September 13, 2022. 35 ROS1+ patients enrolled across five dose levels (25 mg QD – 125 mg QD). Source: Drilon et al., EORTC-NCI-AACR 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ebe59b0-c41a-4616-9b34-4374771123a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.08,
        "y": 0.59
      },
      "kind": "list",
      "text": "Updated Phase 1 Data Shared with FDA: Data cut-off: May 17, 2023. 87 ROS1+ patients enrolled across six dose levels (25 mg QD – 150 mg QD)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98e42ded-2477-4b68-bdf9-a9c9067a2738",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.5,
        "x": 0.43,
        "y": 0.23
      },
      "kind": "list",
      "text": "Rationale for Selection of 100 mg as RP2D: Overall, the company believes these findings to be consistent with the preliminary Phase 1 conclusions reported in October 2022. Favorable tolerability of NVL-520 was observed across all dose levels to date. MTD was not reached, and no clinically significant exposure-response relationships for safety and efficacy were observed across the dose levels evaluated (25 mg – 150 mg daily). The dose level of 100 mg daily maintained steady state plasma levels above all target efficacy thresholds (ROS1 wild type and ROS1 G2032R in both the periphery and in the CNS). Alignment with FDA on RP2D selection",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4027069-e592-4c8e-b882-e77f35ee1358",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.11
      },
      "kind": "title",
      "text": "100 mg QD Selected as Recommended Phase 2 Dose (RP2D) for NVL-520",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70c8e985-3ca3-483d-8d1b-dd624a179b62",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "146e49b6-5ce8-460a-8be8-2d8e25a32bca",
      "evidence": "components include list/bullet",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}